Transaction · 0001193125-26-418114

Narula Sanjeev

Narula Sanjeev, CF, BO, reported a transaction classified as withholding at Phathom Pharmaceuticals, Inc. involving 13485.000000 shares for an estimated $91428.30. Reported holdings after the transaction were 214718.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FCF, BO
PHATPhathom Pharmaceuticals, Inc.
Filing timeOct 08
Trade dateOct 06, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableCalculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$6.81
Pre-filing
1mo ago +32.9%1w ago +8.1%1d ago -1.6%
Returns since
7d30d90d180d1y

PHAT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PHAT since 2026-10-08Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0001193125-26-418114
Common Stock
Transaction date
Oct 06, 2026
Filed Oct 08, 2026, 09:44 PM · 2d delay
Shares
13.4k sh
$6.78 per share
Estimated value
-$91.4k
Computed from shares × price
Holdings after
214k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial & Bus. Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

  2. F2

    Includes 1,488 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2026.

Original filing · 0001193125-26-418114
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PHAT